P2 purinoceptors: Renal pathophysiology and therapeutic potential

Clinical Nephrology

Volumn 78, Issue 2, 2012, Pages 154-163

  Booth, John W R ^a   Tam, Frederick W K ^b   Unwin, Robert J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

ATP; Inflammation; Kidney; P2 purinoceptors; P2x7

Indexed keywords

PURINERGIC P2 RECEPTOR; PURINERGIC P2X1 RECEPTOR; PURINERGIC P2X7 RECEPTOR;

ARTICLE; CHRONIC KIDNEY DISEASE; DIABETES INSIPIDUS; DIABETIC NEPHROPATHY; GLOMERULONEPHRITIS; HUMAN; HYPERTENSION; KIDNEY FIBROSIS; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; RENAL PATHOPHYSIOLOGY; WATER TRANSPORT;

GLOMERULONEPHRITIS; HUMANS; KIDNEY; KIDNEY DISEASES; POLYCYSTIC KIDNEY DISEASES; PURINERGIC P2 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2;

EID: 84865074302     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107325     Document Type: Article

References (92)

1. Burnstock G, Campbell G, Satchell D, Smythe A. Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut. Br J Pharmacol. 1970; 40: 668-688.
2. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev. 2006; 58: 58-86.
3. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev. 2006; 58: 281-341.
4. Khakh BS, North RA. P2X receptors as cell-surface ATP sensors in health and disease. Nature 2006; 442: 527-532.
5. North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002; 82: 1013-1067.
6. Solini A, Iacobini C, Ricci C, Chiozzi P, Amadio L, Pricci F, Di Mario U, Di Virgilio F, Pugliese G. Purinergic modulation of mesangial extracellular matrix production: role in diabetic and other glomerular diseases. Kidney Int. 2005; 67: 875-885.
7. Vekaria RM, Unwin RJ, Shirley DG. Intraluminal ATP concentrations in rat renal tubules. J Am Soc Nephrol. 2006; 17: 1841-1847.
8. Praetorius HA, Leipziger J. ATP release from nonexcitable cells. Purinergic Signal. 2009; 5: 433-446.
9. Turner CM, Vonend O, Chan C, Burnstock G, Unwin RJ. The pattern of distribution of selected ATP-sensitive P2 receptor subtypes in normal rat kidney: an immunohistological study. Cells Tissues Organs. 2003; 175: 105-117.
10. Unwin RJ, Bailey MA, Burnstock G. Purinergic signaling along the renal tubule: the current state of play. News Physiol Sci. 2003; 18: 237-241.
11. Shirley DG, Vekaria RM, Sévigny J. Ectonucleotidases in the kidney. Purinergic Signal. 2009; 5: 501-511.
12. Byrne C, Ford D, Gilg J, Ansell D, Feehally J. UK Renal Registry 12th Annual Report (December 2009): chapter 3: UK ESRD incident rates in 2008: national and centre-specific analyses. Nephron Clin Pract. 2010; 115 (Suppl 1): c9-c39.
13. Tam FW. Current pharmacotherapy for the treatment of crescentic glomerulonephritis. Expert Opin Investig Drugs. 2006; 15: 1353-1369.
14. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science (New York, N.Y. 1996; 272: 735-738.
15. Taylor SR, Gonzalez-Begne M, Dewhurst S, Chimini G, Higgins CF, Melvin JE, Elliott JI. Sequential shrinkage and swelling underlie P2X7-stimulated lymphocyte phosphatidylserine exposure and death. J Immunol. 2008; 180: 300-308.
16. Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Melchiorri L, Baricordi OR, Di Virgilio F. Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J Immunol. 1997; 159: 1451-1458.
17. Franchi L, Eigenbrod T, Núñez G. Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol. 2009; 183: 792-796.
18. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ, Gabel CA. Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem. 2001; 276: 125-132.
19. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, Di Virgilio F. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol. 2006; 176: 3877-3883.
20. Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci. 2007; 28: 465-472.
21. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CC, Beck PL, Muruve DA, Kubes P. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science (New York, N.Y. 2010; 330: 362-366.
22. McAdoo SP, Tam FW, Pusey CD. Disease models of rapidly progressive glomerulonephritis. Drug Discov Today Dis Models. 2010; 7: 43-50.
23. Turner CM, Tam FW, Lai PC, Tarzi RM, Burnstock G, Pusey CD, Cook HT, Unwin RJ. Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrol Dial Transplant. 2007; 22: 386-395.
24. Taylor SR, Turner CM, Elliott JI, McDaid J, Hewitt R, Smith J, Pickering MC, Whitehouse DL, Cook HT, Burnstock G, Pusey CD, Unwin RJ, Tam FW. P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. J Am Soc Nephrol. 2009; 20: 1275-1281.
25. Keystone EC, Wang MM, Layton M, Hollis S, Mc-Innes IB; on behalf of the D1520C00001 Study Team. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2011.
26. Arulkumaran N, Unwin RJ, Tam FW. A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Investig Drugs. 2011; 20: 897-915.
27. Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest. 1999; 104: 1731-1737.
28. Hohenstein B, Renk S, Lang K, Daniel C, Freund M, Léon C, Amann KU, Gachet C, Hugo CP. P2Y1 gene deficiency protects from renal disease progression and capillary rarefaction during passive crescentic glomerulonephritis. J Am Soc Nephrol. 2007; 18: 494-505.
29. Rost S, Daniel C, Schulze-Lohoff E, Bäumert HG, Lambrecht G, Hugo C. P2 receptor antagonist PPADS inhibits mesangial cell proliferation in experimental mesangial proliferative glomerulonephritis. Kidney Int. 2002; 62: 1659-1671.
30. Bagchus WM, Hoedemaeker PJ, Rozing J, Bakker WW. Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. Laboratory investigation; a journal of technical methods and pathology. 1986; 55: 680-687.
31. Hugo C, Shankland SJ, Bowen-Pope DF, Couser WG, Johnson RJ. Extraglomerular origin of the mesangial cell after injury. A new role of the juxtaglomerular apparatus. J Clin Invest. 1997; 100: 786-794.
32. Schulze-Lohoff E, Zanner S, Ogilvie A, Sterzel RB. Extracellular ATP stimulates proliferation of cultured mesangial cells via P2-purinergic receptors. Am J Physiol. 1992; 263: F374-F383.
33. Harada H, Chan CM, Loesch A, Unwin R, Burnstock G. Induction of proliferation and apoptotic cell death via P2Y and P2X receptors, respectively, in rat glomerular mesangial cells. Kidney Int. 2000; 57: 949-958.
34. Osmond DA, Inscho EW. P2X(1) receptor blockade inhibits whole kidney autoregulation of renal blood flow in vivo. Am J Physiol Renal Physiol. 2010; 298: F1360-F1368.
35. Ren Y, Garvin JL, Liu R, Carretero OA. Role of macula densa adenosine triphosphate (ATP) in tubuloglomerular feedback. Kidney Int. 2004; 66: 1479-1485.
36. Peti-Peterdi J. Calcium wave of tubuloglomerular feedback. Am J Physiol Renal Physiol. 2006; 291: F473-F480.
37. Toma I, Bansal E, Meer EJ, Kang JJ, Vargas SL, Peti-Peterdi J. Connexin 40 and ATP-dependent intercellular calcium wave in renal glomerular endothelial cells. Am J Physiol Regul Integr Comp Physiol. 2008; 294: R1769-R1776.
38. Sipos A, Vargas S, Peti-Peterdi J. Direct demonstration of tubular fluid flow sensing by macula densa cells. Am J Physiol Renal Physiol. 2010; 299: F1087-F1093.
39. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008; 19: 433-442.
40. Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA, Tschopp J, Trpkov K, Hemmelgarn BR, Beck PL, Muruve DA. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010; 21: 1732-1744.
41. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol. 2003; 14: 1358-1373.
42. Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius FC III. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes. 2008; 57: 1439-1445.
43. Solini A, Santini E, Chimenti D, Chiozzi P, Pratesi F, Cuccato S, Falzoni S, Lupi R, Ferrannini E, Pugliese G, Di Virgilio F. Multiple P2X receptors are involved in the modulation of apoptosis in human mesangial cells: evidence for a role of P2X4. Am J Physiol Renal Physiol. 2007; 292: F1537-F1547.
44. Solini A, Chiozzi P, Falzoni S, Morelli A, Fellin R, Di Virgilio F. High glucose modulates P2X7 receptor-mediated function in human primary fibroblasts. Diabetologia. 2000; 43: 1248-1256.
45. Solini A, Chiozzi P, Morelli A, Adinolfi E, Rizzo R, Baricordi OR, Di Virgilio F. Enhanced P2X7 activity in human fibroblasts from diabetic patients: a possible pathogenetic mechanism for vascular damage in diabetes. Arterioscler Thromb Vasc Biol. 2004; 24: 1240-1245.
46. Vonend O, Turner CM, Chan CM, Loesch A, Dell'Anna GC, Srai KS, Burnstock G, Unwin RJ. Glomerular expression of the ATP-sensitive P2X receptor in diabetic and hypertensive rat models. Kidney Int. 2004; 66: 157-166.
47. Karczewska J, Piwkowska A, Rogacka D, Ste{ogonek}piński J, Angielski S, Jankowski M. Purinergic modulation of glucose uptake into cultured rat podocytes: effect of diabetic milieu. Biochem Biophys Res Commun. 2011; 404: 723-727.
48. Reddy GR, Kotlyarevska K, Ransom RF, Menon RK. The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy? Curr Opin Nephrol Hypertens. 2008; 17: 32-36.
49. Klahr S. Urinary tract obstruction. Semin Nephrol. 2001; 21: 133-145.
50. Gonçalves RG, Gabrich L, Rosário A Jr, Takiya CM, Ferreira ML, Chiarini LB, Persechini PM, Coutinho-Silva R, Leite M Jr. The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int. 2006; 70: 1599-1606.
51. Riteau N, Gasse P, Fauconnier L, Gombault A, Couegnat M, Fick L, Kanellopoulos J, Quesniaux VF, Marchand-Adam S, Crestani B, Ryffel B, Couillin I. Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med. 2010; 182: 774-783.
52. Ponnusamy M, Ma L, Gong R, Pang M, Chin YE, Zhuang S. P2X7 receptors mediate deleterious renal epithelial-fibroblast cross talk. Am J Physiol Renal Physiol. 2011; 300: F62-F70.
53. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009; 76: 149-168.
54. Yoder BK. Role of primary cilia in the pathogenesis of polycystic kidney disease. J Am Soc Nephrol. 2007; 18: 1381-1388.
55. Wilson PD, Hovater JS, Casey CC, Fortenberry JA, Schwiebert EM. ATP release mechanisms in primary cultures of epithelia derived from the cysts of polycystic kidneys. J Am Soc Nephrol. 1999; 10: 218-229.
56. Communi D, Janssens R, Suarez-Huerta N, Robaye B, Boeynaems JM. Advances in signalling by extracellular nucleotides. the role and transduction mechanisms of P2Y receptors. Cell Signal. 2000; 12: 351-360.
57. Mangoo-Karim R, Uchic M, Lechene C, Grantham JJ. Renal epithelial cyst formation and enlargement in vitro: dependence on cAMP. Proc Natl Acad Sci USA. 1989; 86: 6007-6011.
58. Schwiebert EM, Wallace DP, Braunstein GM, King SR, Peti-Peterdi J, Hanaoka K, Guggino WB, Guay-Woodford LM, Bell PD, Sullivan LP, Grantham JJ, Taylor AL. Autocrine extracellular purinergic signaling in epithelial cells derived from polycystic kidneys. Am J Physiol Renal Physiol. 2002; 282: F763-F775.
59. Turner CM, King BF, Srai KS, Unwin RJ. Antagonism of endogenous putative P2Y receptors reduces the growth of MDCK-derived cysts cultured in vitro. Am J Physiol Renal Physiol. 2007; 292: F15-F25.
60. Buchholz B, Teschemacher B, Schley G, Schillers H, Eckardt KU. Formation of cysts by principallike MDCK cells depends on the synergy of cAMP- and ATP-mediated fluid secretion. J Mol Med (Berl). 2011; 89: 251-261.
61. Hillman KA, Johnson TM, Winyard PJ, Burnstock G, Unwin RJ, Woolf AS. P2X(7) receptors are expressed during mouse nephrogenesis and in collecting duct cysts of the cpk/cpk mouse. Exp Nephrol. 2002; 10: 34-42.
62. Hillman KA, Woolf AS, Johnson TM, Wade A, Unwin RJ, Winyard PJ. The P2X7 ATP receptor modulates renal cyst development in vitro. Biochem Biophys Res Commun. 2004; 322: 434-439.
63. Chang MY, Lu JK, Tian YC, Chen YC, Hung CC, Huang YH, Chen YH, Wu MS, Yang CW, Cheng YC. Inhibition of the P2X7 receptor reduces cystogenesis in PKD. J Am Soc Nephrol. 2011; 22: 1696-1706.
64. Praetorius HA, Spring KR. Bending the MDCK cell primary cilium increases intracellular calcium. J Membr Biol. 2001; 184: 71-79.
65. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, Elia AE, Lu W, Brown EM, Quinn SJ, Ingber DE, Zhou J. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet. 2003; 33: 129-137.
66. Praetorius HA, Leipziger J. Released nucleotides amplify the cilium-dependent, flow-induced [Ca2+]i response in MDCK cells. Acta Physiol (Oxf). 2009; 197: 241-251.
67. Jensen ME, Odgaard E, Christensen MH, Praetorius HA, Leipziger J. Flow-induced [Ca2+]i increase depends on nucleotide release and subsequent purinergic signaling in the intact nephron. J Am Soc Nephrol. 2007; 18: 2062-2070.
68. Xu C, Shmukler BE, Nishimura K, Kaczmarek E, Rossetti S, Harris PC, Wandinger-Ness A, Bacallao RL, Alper SL. Attenuated, flow-induced ATP release contributes to absence of flow-sensitive, purinergic Cai2+ signaling in human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol. 2009; 296: F1464-F1476.
69. Calvet JP. Cilia in PKD - letting it all hang out. J Am Soc Nephrol. 2002; 13: 2614-2616.
70. Kishore BK, Chou CL, Knepper MA. Extracellular nucleotide receptor inhibits AVP-stimulated water permeability in inner medullary collecting duct. Am J Physiol. 1995; 269: F863-F869.
71. Wildman SS, Boone M, Peppiatt-Wildman CM, Contreras-Sanz A, King BF, Shirley DG, Deen PM, Unwin RJ. Nucleotides downregulate aquaporin 2 via activation of apical P2 receptors. J Am Soc Nephrol. 2009; 20: 1480-1490.
72. Welch BD, Carlson NG, Shi H, Myatt L, Kishore BK. P2Y2 receptor-stimulated release of prostaglandin E2 by rat inner medullary collecting duct preparations. Am J Physiol Renal Physiol. 2003; 285: F711-F721.
73. Kishore BK, Krane CM, Miller RL, Shi H, Zhang P, Hemmert A, Sun R, Nelson RD. P2Y2 receptor mRNA and protein expression is altered in inner medullas of hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005; 288: F1164-F1172.
74. Zhang Y, Sands JM, Kohan DE, Nelson RD, Martin CF, Carlson NG, Kamerath CD, Ge Y, Klein JD, Kishore BK. Potential role of purinergic signaling in urinary concentration in inner medulla: insights from P2Y2 receptor gene knockout mice. Am J Physiol Renal Physiol. 2008; 295: F1715-F1724.
75. Zhang Y, Nelson RD, Carlson NG, Kamerath CD, Kohan DE, Kishore BK. Potential role of purinergic signaling in lithium-induced nephrogenic diabetes insipidus. Am J Physiol Renal Physiol. 2009; 296: F1194-F1201.
76. Zhang Y, Kohan DE, Nelson RD, Carlson NG, Kishore BK. Potential involvement of P2Y2 receptor in diuresis of postobstructive uropathy in rats. Am J Physiol Renal Physiol. 2010; 298: F634-F642.
77. Palomino-Doza J, Rahman TJ, Avery PJ, Mayosi BM, Farrall M, Watkins H, Edwards CR, Keavney B. Ambulatory blood pressure is associated with polymorphic variation in P2X receptor genes. Hypertension. 2008; 52: 980-985.
78. Wang Z, Nakayama T, Sato N, Izumi Y, Kasamaki Y, Ohta M, Soma M, Aoi N, Ozawa Y, Ma Y. The purinergic receptor P2Y, G-protein coupled, 2 (P2RY2) gene associated with essential hypertension in Japanese men. J Hum Hypertens. 2010; 24: 327-335.
79. Pochynyuk O, Bugaj V, Rieg T, Insel PA, Mironova E, Vallon V, Stockand JD. Paracrine regulation of the epithelial Na+ channel in the mammalian collecting duct by purinergic P2Y2 receptor tone. J Biol Chem. 2008; 283: 36599-36607.
80. Wildman SS, Marks J, Turner CM, Yew-Booth L, Peppiatt-Wildman CM, King BF, Shirley DG, Wang W, Unwin RJ. Sodium-dependent regulation of renal amiloride-sensitive currents by apical P2 receptors. J Am Soc Nephrol. 2008; 19: 731-742.
81. Rieg T, Bundey RA, Chen Y, Deschenes G, Junger W, Insel PA, Vallon V. Mice lacking P2Y2 receptors have salt-resistant hypertension and facilitated renal Na+ and water reabsorption. FASEB J. 2007; 21: 3717-3726.
82. Yamamoto K, Sokabe T, Matsumoto T, Yoshimura K, Shibata M, Ohura N, Fukuda T, Sato T, Sekine K, Kato S, Isshiki M, Fujita T, Kobayashi M, Kawamura K, Masuda H, Kamiya A, Ando J. Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. Nat Med. 2006; 12: 133-137.
83. Ji X, Naito Y, Hirokawa G, Weng H, Hiura Y, Takahashi R, Iwai N. P2X(7) receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertens Res. 2012; 35: 173-179.
84. Graciano ML, Nishiyama A, Jackson K, Seth DM, Ortiz RM, Prieto-Carrasquero MC, Kobori H, Navar LG. Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension. Am J Physiol Renal Physiol. 2008; 294: F161-F169.
85. Loutzenhiser R, Griffin KA, Bidani AK. Systolic blood pressure as the trigger for the renal myogenic response: protective or autoregulatory? Curr Opin Nephrol Hypertens. 2006; 15: 41-49.
86. Inscho EW, Cook AK, Clarke A, Zhang S, Guan Z. P2X1 receptor-mediated vasoconstriction of afferent arterioles in angiotensin II-infused hypertensive rats fed a high-salt diet. Hypertension. 2011; 57: 780-787.
87. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502.
88. Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009; 10: 241-247.
89. Yan Z, Khadra A, Li S, Tomic M, Sherman A, Stojilkovic SS. Experimental characterization and mathematical modeling of P2X7 receptor channel gating. J Neurosci. 2010; 30: 14213-14224.
90. Pelegrin P. The many ways for P2X7 receptor pore dilatation. Br J Pharmacol. 2011; 163: 908-911.
91. Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J. 2006; 25: 5071-5082.
92. Di Virgilio F, Ferrari D, Adinolfi E. P2X(7): a growth-promoting receptor-implications for cancer. Purinergic Signal. 2009; 5: 251-256.